Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Methods of treating disorders associated with excess or unwanted killer cell lectin-like receptor subfamily g member 1 (KLRG1) expressing t cells with KLRG1 depleting antibodies

Methods of treating disorders associated with excess or unwanted killer cell lectin-like receptor subfamily g member 1 (KLRG1) expressing t cells with KLRG1 depleting antibodies

US Patent 12139541 · Granted Nov 12, 2024

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Interferon beta antibodies and uses thereof2025
Chemically-defined baculovirus expression system2025
Anti-KLRG1 antibodies2025
Anti-KLRG1 antibodies2025
Antibodies that bind interleukin 13 and methods of use2025
Recombinant ROBO2 proteins, compositions, methods and uses thereof2024
Interferon beta antibodies and uses thereof2024
Anti-ROBO2 antibodies, compositions, methods and uses thereof2022
KLRG1 antagonist signaling therapy2022
KLRG1 antagonist signaling therapy2022
Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodi2021
Killer cell lectin-like receptor subfamily G member 1 (KLRG1) depleting antibodi2021